Jakie badania zostaną zaprezentowane na kongresie ACC 2016

870 0
Udostępnij
870 0
ACC16

Już bardzo niedługo, bo już 2 kwietnia, rozpocznie się w Chicago jedno z najważniejszych naukowych wydarzeń roku w dziedzinie medycyny – międzynarodowa konferencja kardiologiczna Amerykańskiego Towarzystwa Kardiologicznego (American College of Cardiology, ACC).

A oto, jakie wyniki zostaną przedstawione podczas sesji Late-Breaking Clinical Trials, czyli zarezerwowanych dla prezentacji najważniejszych badań.

 

Sobota, 2 kwietnia

Partner 2: Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate Risk Patients with Aortic Stenosis: Final Results from the Randomized Placement of Aortic Transcatheter Valves 2 Study
HOPE 3: Blood Pressure Lowering in People at Moderate Risk
HOPE 3: Effects of Combined Lipid and BP-Lowering on Cardiovascular Disease in a Moderate Risk Global Primary Prevention Population

Niedziela, 3 kwietnia

ACCELERATE: Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Events: Results of the ACCELERATE trial
GAUSS-3: Comparison of PCSK9 Inhibitor Evolocumab Versus Ezetimibe in Statin-intolerant Patients: The Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects 3 (GAUSS-3) Trial
FH Mutations: Low-density Lipoprotein Cholesterol, Familial Hypercholesterolemia Mutation Status and Risk for Coronary Artery Disease
Stepathlon: Reproducible Impact of a Global Mobile Health (mHealth) Mass-Participation Physical Activity Intervention on Step Count, Sitting Behavior and Weight: the Stepathlon Cardiovascular Health Study
Low Risk Chest Pain: Involving Patients with Low Risk Chest Pain in Discharge Decisions: A Multicenter Trial
DANish (DEFERred stent): The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: DEFERred stent implantation in connection with primary PCI
DANish (iPOST conditioning): The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: iPOSTconditioning during primary PCI
Early-BAMI: Effect Of Early Administration Of Intravenous Beta Blockers In Patients With ST-elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. The Early-BAMI trial
Sapien 3: Sapien 3 Transcatheter Aortic Valve Replacement versus Surgery in Intermediate-Risk Patients with Severe Aortic Stenosis: A Propensity-Matched Comparison of One-Year Outcomes
TAVR Volume/Outcome: Relationship Between Procedure Volume and Outcome for Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: Insights from the STS/ACC TVT Registry

Poniedziałek, 4 kwietnia

Resuscitation Outcomes: Antiarrhythmic Drugs for Shock-Refractory Out-of-Hospital Cardiac Arrest: The Resuscitation Outcomes Consortium Amiodarone, Lidocaine or Placebo Study
FIRE AND ICE: Largest Randomized Trial Demonstrates an Effective Ablation of Atrial Fibrillation: the FIRE AND ICE Trial
Rate v Rhythm: A Randomized Trial of Rate Control Versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery
LATITUDE-TIMI 60: The Losmapimod To Inhibit P38 MAP Kinase As A Therapeutic Target And Modify Outcomes After An Acute Coronary Syndrome (LATITUDE-TIMI 60) Trial: Primary Results Of Part A
CARIN: CMX-2043 for Prevention of Contrast Induced Acute Kidney Injury: The Primary Results of the CARIN Trial
ATMOSPHERE: Direct Renin-inhibition With Aliskiren Alone And In Combination With Enalapril, Compared With Enalapril, In Heart Failure (the ATMOSPHERE Trial)
TRUE-AHF: Effect of Ularitide on Short- and Long-Term Clinical Course of Patients with Acutely Decompensated Heart Failure: Primary Results of the TRUE-AHF Trial
IxCell-DCM: The Final Results of the IxCell-DCM Trial: Transendocardial Injection of Ixmyelocel-T in Patients with Ischemic Dilated Cardiomyopathy
INOVATE-HF: The Effect of Vagal Nerve Stimulation in Heart Failure: Primary Results of the INcrease Of VAgal TonE in chronic Heart Failure (INOVATE-HF) Trial
IMPEDANCE-HF: Non-invasive Lung IMPEDANCE-Guided Preemptive Treatment in Chronic Heart Failure Patients: a Randomized Controlled Trial (IMPEDANCE-HF trial)


Aplikacja towarzysząca konferencji:
iOS, Android.

 

Udostępnij
Artykuł w kategoriach

Dołącz do dyskusji


Treść na stronie do której próbujesz uzyskać dostęp jest przeznaczona tylko dla lekarzy. Proszę o odpowiedź na pytanie: Czy jesteś lekarzem?

Oświadczam, że jestem lekarzem

Powered by WordPress Popup